PRESCRIPTION OMEGA-3 FATTY ACIDS IMPROVE LOW-DENSITY LIPOPROTEIN SUBCLASS DISTRIBUTION WITHOUT INCREASING LOW-DENSITY LIPOPROTEIN PARTICLE CONCENTRATION IN STATIN-TREATED PATIENTS WITH MIXED DYSLIPIDEMIA  by Maki, Kevin C. et al.
E522
JACC April 5, 2011
Volume 57, Issue 14
   GENERAL CARDIOLOGY: HYPERTENSION, PREVENTION AND LIPIDS
PRESCRIPTION OMEGA-3 FATTY ACIDS IMPROVE LOW-DENSITY LIPOPROTEIN SUBCLASS 
DISTRIBUTION WITHOUT INCREASING LOW-DENSITY LIPOPROTEIN PARTICLE CONCENTRATION IN 
STATIN-TREATED PATIENTS WITH MIXED DYSLIPIDEMIA
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 3:30 p.m.-4:45 p.m.
Session Title: The Pros and Cons of Statin Therapy
Abstract Category: 14. Pharmacology/Hormones/Lipids—Basic
Session-Poster Board Number: 1045-276
Authors: Kevin C. Maki, Mary R. Dicklin, Susan L. Johnson, Mayadah Shabbout, Harold E. Bays, Provident Clinical Research, Glen Ellyn, IL, 
GlaxoSmithKline, Research Triangle Park, NC
Background:  Recent data suggest that a substantial number of statin-treated patients may experience a decrease in low-density lipoprotein 
particle (LDL-P) size, which might contribute to residual atherosclerotic risk. This post-hoc analysis evaluated atorvastatin plus placebo and 
atorvastatin plus prescription omega-3 fatty acids (POM3) on LDL-P size and concentration in mixed dyslipidemic patients.
Methods:  Double-blind, randomized, 8-week trial of escalating doses of open-label atorvastatin 10, 20, 40 mg/d plus placebo compared with 
escalating atorvastatin plus POM3 4 g/d.
Results:  As shown in the table, treatment difference compared to placebo in change from baseline, addition of 10 mg/d POM3 significantly 
increased median change from baseline LDL-P size (p=0.0011) without altering the total LDL-P concentration (p=0.1813). POM3 treated subjects 
showed significant shifts in LDL subclass distribution, including reduction in small LDL-P concentration (p=0.0255 vs. placebo) and an increase in 
large LDL-P concentration (p<0.0001 vs. placebo). Also, a significantly larger fraction of subjects switched from pattern B (predominance of small 
LDL-P) to pattern A (predominance of large LDL-P) in the POM3 group (18.5% vs. 8.5%, p=0.0241). Findings were consistent as atorvastatin dose 
was escalated. 
Parameter
Placebo +
Atorvastatin 10 mg/d
(n=118)
POM3 4 g/d +
Atorvastatin 10 mg/d
(n=119)
95% CI
P-Value
Median (25th, 75th percentiles)
LDL-P Size, nm
Baseline 19.8 (19.6,19.9) 19.7 (19.5, 20.0) -0.40, -0.10
Change from BL 0.1 (-0.2, 0.4) 0.3 (-0.1, 0.8) 0.0011
Total LDL-P, nmol/L
Baseline 1957 (1722, 2212) 1920 (1625, 2195) -57, 126
Change from BL -601 (-798, -420) -679 (-881, -384) 0.1813
Small LDL-P, nmol/L
Baseline 1718 (1436, 1920) 1659 (1364, 1919) -19, 176
Change from BL -543 (-756, -346) -625 (-901, -363) 0.0255
Large LDL-P, nmol/L
Baseline 132 (64, 224) 128 (66, 284) -92, -31
Change from BL -12 (-93, 41) 50 (-48, 125) <0.0001
Conclusions:  The addition of 4 g/d POM3 to atorvastatin 10 mg/d improved LDL subclass distribution compared to placebo, without altering 
LDL-P concentration in patients with mixed dyslipidemia.
